Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

GSK stories

Nov 6, 2026

GSK and Moderna settle patent dispute over COVID and RSV vaccines

GSK has settled lawsuits accusing Moderna's COVID-19 vaccines Spikevax and mNEXSPIKE and RSV shot mResvia of infringing its patents, resolving a major intellectual property dispute between the two drugmakers.

Nov 6, 2026·2 sources
00
Oct 29, 2026

Flagship Pioneering merges Etiome, Cellarity and Empress Therapeutics into Etcelera

Biotechnology startup creator Flagship Pioneering is combining three of its portfolio companies—Etiome, Cellarity, and Empress Therapeutics—into a new venture called Etcelera. The merged company will use artificial intelligence and drug discovery tools to predict which experimental medicines might succeed in clinical trials.

Oct 29, 2026·2 sources
00
Oct 26, 2026

GSK to nearly double cancer drugs in clinical trials by 2027

GSK expects to nearly double the number of cancer medicines it is testing in clinical trials next year, according to a Wall Street Journal interview with a company scientist. The expansion follows a dealmaking spree as the British drugmaker accelerates its return to oncology.

Oct 26, 2026·5 sources
00
Oct 20, 2026

FDA approves GSK's hepatitis B drug Hibsago

The FDA approved GSK's hepatitis B drug Hibsago, allowing patients with the liver infection to maintain viral control after stopping long-term treatment. The approval offers a new treatment option for chronic hepatitis B patients.

Oct 20, 2026·2 sources
00
Oct 14, 2026

GSK to cut up to 1,217 jobs in Belgium as part of restructuring plan

GSK announced plans to make up to 1,217 workers redundant from its Belgian sites, marking the first major action in the drugmaker's three-year plan to save £1.9 billion in costs.

Oct 14, 2026·2 sources
00
Oct 9, 2026

GSK to invest $800 million in Pennsylvania biologics manufacturing hub

GSK is investing more than $800 million to expand its Upper Merion Township, Pennsylvania site into a biopharmaceutical manufacturing and research hub. The project will create more than 300 jobs over the next five years and involves demolishing existing buildings to construct new facilities for clinical and commercial biologics production.

Oct 9, 2026·4 sources
00
Sep 15, 2026

GSK acquires Chimagen's multiple myeloma drug candidate for up to $750 million

GSK announced it will acquire a T cell engager for blood cancer from China-based Chimagen Biosciences for up to $750 million, marking its latest deal in the oncology space.

Sep 15, 2026·2 sources
00
Sep 1, 2026

GSK advances mRNA flu vaccine to late-stage trial after strong mid-stage results

GSK will advance its mRNA-based seasonal influenza vaccine to late-stage trials after mid-stage data showed it generated stronger immune responses than currently approved flu vaccines.

Sep 1, 2026·2 sources
00
Jul 30, 2026

GSK and Relation Therapeutics announce $110 million AI drug discovery partnership

British biotech firm Relation Therapeutics has entered into a research collaboration with pharmaceutical giant GSK worth up to $110 million to generate human cellular datasets and train AI models for identifying potential new drug targets.

Jul 30, 2026·1 source
00
Jul 28, 2026

GSK partner Hansoh Pharmaceutical's bone cancer drug meets primary endpoint in second Phase III trial in China

Hansoh Pharmaceutical announced positive results from the ARTEMIS-011 Phase III trial in China, with its experimental drug Ris-Rez meeting the primary endpoint of progression-free survival in relapsed bone cancer patients. This marks the second Phase III success for the drug, strengthening GSK's oncology portfolio through its licensing partnership with the Chinese biotech.

Jul 28, 2026·3 sources
00
Jul 22, 2026

GSK receives FDA approval for Jideytro lung cancer drug

The FDA approved GSK's Jideytro for treating a form of lung cancer, nearly two months after the British drugmaker acquired the treatment as part of a $10.6 billion deal.

Jul 22, 2026·1 source
00
Jul 17, 2026

GSK halts development of chronic cough drug after late-stage trial failures

GSK discontinued development of an experimental chronic cough treatment after it failed to meet key goals in two late-stage clinical trials, with the company stating it was unlikely to transform patient care. Shares fell about 4%.

Jul 17, 2026·2 sources
00
Jul 13, 2026

GSK's Cancer Drug Jemperli Meets Primary Goal in Mid-Stage Rectal Cancer Trial

GSK announced its cancer drug Jemperli achieved clinically significant rates of patients showing no detectable signs of cancer for one year or more in a mid-stage rectal cancer trial.

Jul 13, 2026·1 source
00
Jun 9, 2026

GSK Acquires Nuvalent for $10.6 Billion to Expand Cancer Drug Portfolio

UK pharmaceutical giant GSK has entered an agreement to acquire U.S.-based cancer drugmaker Nuvalent for $10.6 billion, adding targeted cancer therapies to its portfolio in one of the year's largest biopharma acquisitions.

Jun 9, 2026·3 sources
00
May 28, 2026

GSK's Experimental Hepatitis B Drug Achieves Functional Cure in Nearly 1 in 5 Patients in Late-Stage Trials

GSK reported that its experimental chronic hepatitis B drug helped nearly one in five patients achieve a functional cure in late-stage studies, vastly outpacing current treatments and raising hopes for a finite treatment course as an alternative to lifelong therapy.

May 28, 2026·2 sources
00

Top claims

  • ▪GSK and Moderna settled all pending patent infringement lawsuits regarding Moderna's COVID-19 vaccines Spikevax and mNEXSPIKE and RSV vaccine mResvia
  • ▪Moderna reported third-quarter 2026 total revenue of $1.313 billion, representing a 29% increase from $1.016 billion in the third quarter of 2025
  • ▪The U.S. Food and Drug Administration granted accelerated approval for Moderna's mFLUSIVA for adults aged 65 and older, contingent on a confirmatory efficacy study

Topics

COVID-19 vaccinesPharmaceutical earningsIntellectual property & tradeMRNA vaccine technologyPharmaceutical IndustryPharmaceutical patentsAI in healthcareBiotechnologyMergers & acquisitions (M&A)Biotech startupMergers and acquisitionsDrug discoveryAI applicationsAI drug discoveryMachine learningClinical trialsCancerOncologyCancer & OncologyDrug developmentCorporate strategyAntiviral therapyDrug Policy, Pricing & ApprovalFDA regulatory approvalChronic disease managementFDA drug approvalInfectious diseaseHepatitis B treatmentDrug Approval and Clinical TrialsOutbreak monitoring & surveillanceCorporate restructuringLabor displacementJob creationPharmaVaccines and Immunization PolicyVaccine development and innovationAI in drug discoveryAI for developersCancer treatment breakthroughsCancer Treatment & TherapiesClinical Trial Design & EvaluationClinical trial endpointsFDA drug approval processNew drug application (NDA) processCancer TypesImmunotherapyTargeted cancer therapyInfectious Disease and OutbreaksClinical evaluation

Related entities

DelawarePfizerUnited StatesUnited KingdomHepatitis BBelgiumChinaInfluenza VaccineImmunologyChinaChronic cough